Pembrolizumab for Early Triple-Negative Breast Cancer

Peter Schmid et al. · PI Medical Director

Primary endpoint

Pathological complete response (pCR) rate using the definition of ypT0/Tis ypN0 (i.e., no invasive residual in breast or nodes; noninvasive breast residuals allowed) at the time of definitive surgery

Population

Triple Negative Breast Neoplasms; n=1174

doi:10.1056/NEJMoa1910549

Historical

Current

Future

3 noemes

Historical

1 noeme

Published findings from this trial. Vote whether the expert body still believes each noeme stands given current evidence.

The KEYNOTE-522 trial's stated primary conclusion — Neoadjuvant pembrolizumab + chemotherapy increases pathologic complete response rate in triple-negative breast cancer. — replicates in independent cohorts.

oncology

Current

1 noeme

Noemes tracking active replication, subgroup analysis, or long-term follow-up. Vote on the likelihood the original effect holds.

Recent follow-up analyses of KEYNOTE-522 are confirming the original effect size in real-world data.

oncology

Future

1 noeme

Open forecast horizons tied to this trial. Vote your probability that each resolves TRUE by the declared horizon.

By 2028, neoadjuvant checkpoint inhibition will be standard-of-care for stage II–III TNBC across major oncology guidelines.

oncology

71%